Prothena to Report Second Quarter 2026 Financial Results on August 6
核心洞察
Prothena Corporation plc (搜索) announced it will release its second quarter and first six months of 2026 financial results on Thursday, August 6, 2026, after U.S. market close.
The company will not hold a conference call in conjunction with the earnings release, consistent with past practice.
Prothena is a late-stage clinical biotechnology company focused on protein dysregulation, advancing therapeutics for neurodegenerative and rare peripheral amyloid diseases.
Prothena Corporation plc (搜索) (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2026 financial results on Thursday, August 6, 2026, after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on August 6.
Pipeline and Therapeutic Focus
Prothena is advancing a pipeline of therapeutic candidates across multiple neurodegenerative and rare peripheral amyloid diseases. The company's portfolio includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson's disease (搜索), ATTR amyloidosis with cardiomyopathy (搜索), Alzheimer's disease (搜索), Amyotrophic lateral sclerosis (搜索) (ALS), and a number of other neurodegenerative diseases.
The company's approach is grounded in decades of research into protein dysregulation, with a focus on integrating scientific insights around neurological dysfunction and the biology of misfolded proteins.
CYTOPE Technology Platform
Prothena is developing and applying CYTOPE, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific macromolecular effectors. This platform represents a key component of the company's scientific strategy for addressing challenging therapeutic targets.
Corporate Information
Prothena Corporation plc (搜索) is headquartered in Dublin, Ireland, and trades on the NASDAQ under the ticker symbol PRTA. Investor relations inquiries can be directed to Mark Johnson, CFA, Senior Vice President, Head of Investor Relations and Corporate Communications.